Market revenue in 2023 | USD 289.8 million |
Market revenue in 2030 | USD 592.9 million |
Growth rate | 10.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 67.98% in 2023. Horizon Databook has segmented the India blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
According to various statistics, India stands as the third-highest country globally in terms of reported cases of blood cancer, following the U.S. and China. It is further estimated a person in India is diagnosed with blood cancer every 5 minutes, and an estimated 70,000 lives are lost annually due to this disease.
India’s biotech industry is encouraging further innovation and investment in the sector. As the country continues to work toward achieving self-reliance in healthcare. For instance, in October 2023, India's first CAR-T cell therapy, developed by Immuno Act, received approval from the Central Drugs Standard Control Organization (CDSCO).
This is a significant milestone in the country's pursuit to develop innovative cancer treatments. CAR-T cell therapy is a type of immunotherapy that uses genetically modified T-cells to target and kill cancer cells. Immuno Act's therapy is designed to treat B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Horizon Databook provides a detailed overview of country-level data and insights on the India blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into India blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account